503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
Consumer Audit Toolkit

Interactive GLP-1 & Pharmacoeconomic Calculators (2026)

Six free client-side tools powered by Losing Weight RX's DOI-registered open datasets.

Interactive Calculator

Local MedSpa vs. $49 Flat-Rate GLP-1 Savings Calculator

Compare brick-and-mortar bariatric clinic monthly fees against $49/mo Semaglutide and $99/mo Tirzepatide.

DOI-Backed Tool · 10.5281/zenodo.24139315

GLP-1 52-Week Dose-Titration & Cost-Per-Milligram ($/mg) Calculator (2026)

Calculate your exact $/mg active yield and 52-week total spend across 0.25–2.4 mg Semaglutide and 2.5–15 mg Tirzepatide vs tiered subscription clinics.

DOI-Backed Tool · 10.5281/zenodo.24139325

GLP-1 Insurance Deductible & Prior-Authorization vs. $49 Cash-Pay Calculator (2026)

Compare your remaining commercial health plan deductible, monthly copay, and PA step-therapy wait time against immediate $49/mo Semaglutide or $99/mo Tirzepatide cash care.

DOI-Backed Tool · 10.5281/zenodo.24139315

Standard 503A Vial Concentration (mg/mL) to U-100 Syringe Units Reference Verifier (2026)

Educational pharmacy-label reference table verifying how standard 2.5 mg/mL, 5 mg/mL, 10 mg/mL, and 20 mg/mL 503A concentrations map to U-100 insulin syringe graduations.

DOI-Backed Tool · 10.5281/zenodo.24139333

IV Drip Lounge vs. 503A Subcutaneous NAD+ & Glutathione Bioavailability Cost Calculator (2026)

Compare monthly retail IV drip lounge charges and low-absorption oral capsules against $49 first-month / $99 ongoing 503A subcutaneous Glutathione and NAD+ on absorbed mg yield.

DOI-Backed Tool · 10.5281/zenodo.24139333

Oral Sublingual vs. Weekly Injectable GLP-1 Cost & Absorption Estimator (2026)

Compare needle-free daily sublingual dissolving GLP-1 tablets ($49 1st month / $149 ongoing) against weekly $49 Semaglutide / $99 Tirzepatide injections and $969 retail oral tablets.

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in Interactive GLP-1 & Pharmacoeconomic Calculators (2026) is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Harvard Health Publishing, Harvard Medical School. (2024). How does Ozempic work? Understanding GLP-1s for diabetes, weight loss, and beyond. https://www.health.harvard.edu/staying-healthy/how-does-ozempic-work-understanding-glp-1s-for-diabetes-weight-loss-and-beyond
  2. National Heart, Lung, and Blood Institute, National Institutes of Health. (2024). Calculate your body mass index (BMI). https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm
  3. O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet (London, England), 392(10148), 637-649. https://doi.org/10.1016/S0140-6736(18)31773-2
  4. Overgaard, R. V., Navarria, A., Ingwersen, S. H., Bækdal, T. A., & Kildemoes, R. J. (2021). Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clinical pharmacokinetics, 60(10), 1335-1348. https://doi.org/10.1007/s40262-021-01025-x
  5. Samuels, J. M., Ye, F., Irlmeier, R., Silver, H., Srivastava, G., & Spann, M. (2025). Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes, obesity & metabolism, 27(11), 6200-6209. https://doi.org/10.1111/dom.70004
  6. U.S. Food and Drug Administration. (2024). Rybelsus (semaglutide) tablets, for oral use: Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s018lbl.pdf